Tag Archives: Lilly

Generic Sema Now in Canada; Roche Posts Petrelintide + Enicepatide Study; Lilly Posts Ph2 Macupatide + Eloralintide Combo Study in Obesity

Three cardiometabolic-related news items have been observed: Apotex launched generic semaglutide in Canada (view press release); Roche posted a Ph2 obesity combination study (view CT.gov record); and Lilly posted a new macupatide + eloralintide combination study (view CT.gov record). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

ProRx FDA Warning Letter; Lilly Partners with UNICEF

Two cardiometabolic-related news items have been observed: FDA issued a warning letter to ProRx regarding GLP-1RA compounding (view FDA letter) and Lilly partnered with UNICEF (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Makary Resigns; Novo OASIS 4 Data; Altimmune Q1 ’26 Earnings; Lilly SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN Full Data; Insulet Initiates O6 vs. O5 Study

A series of cardiometabolic-related news items has been observed from FDA, Novo Nordisk, Altimmune, Lilly, and Insulet. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Sanofi to Pull Tzield Application from CNPV Program; Zealand Q1 ’26 Earnings; GSK Targets ALK7; Lilly Expands US Manufacturing Investment; Roche Acquires PathAI

A series of cardiometabolic-related news items has been observed from Sanofi, Zealand Pharma, GSK, Lilly, and Roche. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Lilly, Viking, and Merck Q1 ’26 Earnings; FDA Semaglutide and Tirzepatide Compounding Exclusions

A series of cardiometabolic-related news items has been observed from Lilly, Viking Therapeutics, Merck, and FDA. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Additional Foundayo Prescription Trends; Regeneron MFN Deal; Arrowhead Positive CHMP Opinion; Eversense 365 CGM Launches in EU

A series of cardiometabolic-related news items has been observed from Lilly, Regeneron, Arrowhead Pharmaceuticals, and Senseonics. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

New Foundayo DTC Ad; Roche Shares New INN for CT-388; April CHMP Agenda

Three cardiometabolic-related news items have been observed: Lilly aired a new Foundayo DTC ad on social media platforms (view Reddit post); Roche’s CT-388 has been given the INN of enicepatide, which is reflected in two Ph2 studies (view CT.gov record; view CT.gov record); and the CHMP agenda for this month’s meeting (April 20-23) has been released (view here). Below, FENIX provides highlights and insights on the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Early Foundayo Prescription Trends; Kailera Announces IPO Pricing; AZ’s Partner Initiates Ph1 FIH Study of Monthly Dual Agonist; ViCentra Eliminates Waiting Period for Kailedo Patch Pump in Select EU Countries

A series of cardiometabolic-related news items has been observed from Lilly, Kailera Therapeutics, AstraZeneca/CSPC Pharmaceuticals, and ViCentra. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Lilly Shares ACHIEVE-4 Topline Data and Receives CNPV for Orforglipron in T2DM; Novo Initiates AMAZE 2; Pfizer and D&D Pharmatech Research Service Agreement; Abbott Q1 ’26 Earnings; Novartis Ph1 HF Study

A series of cardiometabolic-related news items has been observed from Lilly, Novo Nordisk, Pfizer, Abbott, and Novartis. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

FDA Publishes Foundayo Letter of Approval; Novo Partners with OpenAI for AI Drug Development; Sana T1DM Collaboration; Corbus Doses Last Patient in Ph1 CB1 Study

A series of cardiometabolic-related news items has been observed from FDA/Lilly, Novo Nordisk, Sana Biotechnology, and Corbus Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here